UNSPSC 51171723: Lidamidine hydrochloride

This classification denotes an antidiarrheal agent with the molecular formula C11H16N4O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Q1Q4QJV3V, chemically known as 1-(methylamidino)-3-(2,6-xylyl)urea monohydrochloride but more generally known as lidamidine hydrochloride, which bears US NIH Compound Identifier 47509. European Medicines Agency schedules Lidamidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35843.

Most nations, for tariff and trade purposes, schedule lidamidine hydrochloride under HS 29252900 and SITC 51482. As of Q4 2014, LIDAMIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Lidamidine hydrochloride bears US NLM identifiers UMLS ID C0771745 and NCI Concept Code C82241. SMILES: CC1CCCC(C1NC(=O)NC(=N)NC)C.CL.

UNSPSC 51171723 Lidamidine hydrochloride is a Commodity code that maps to state and local procurement activity centered on pharmaceutical testing and drug-screening services rather than the specific active pharmaceutical ingredient its name suggests. State and local buying under this code reflects demand for specimen collection, immunoassay screening, and confirmatory drug-testing capabilities supporting criminal justice and public health programs. Issuing bodies include county criminal justice departments, state health and human services agencies, and cooperative purchasing alliances spanning multiple state and local jurisdictions. The scope encompasses staffed collection sites, laboratory screening and confirmation (LC/MS/MS, GC/MS, oral fluid, and hair testing), electronic reporting systems, and SAMHSA or state laboratory certification.

Recent activity centers in Texas, where Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services with proposals due July 23, 2026 at 2:00 p.m., estimated contract value of $600,000, a two-year initial term commencing September 1, 2026 with three optional one-year renewals, and pricing structured on a per-test basis across three service models (screening only, screening with confirmation, and automatic confirmation of positives). The Texas Health and Human Services Commission posted RFI HHS0017013 on March 27, 2026 with response deadline April 3, 2026, seeking vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit managers and wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., with proposals due March 26, 2026 and contract effectiveness July 1, 2026.